NAS:CNCE (USA) Also trade in: Germany

Concert Pharmaceuticals Inc

$ 10.82 -0.55 (-4.84%)
Volume: 144,458 Avg Vol (1m): 351,385
Market Cap $: 257.47 Mil Enterprise Value $: 98.44 Mil
P/E (TTM): 0.00 P/B: 1.68
Earnings Power Value -15338.07
Net Current Asset Value 5.45
Tangible Book 6.37
Projected FCF 5.83
Median P/S Value 0.95
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
75.32% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CNCE: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.34, Med: 10000, Max: 10000
Current: 10000
1.34
10000
Equity-to-Asset 0.82
Equity-to-Asset ranked higher than
86.11% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
CNCE: 0.82
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -3.22, Med: 0.85, Max: 0.93
Current: 0.82
-3.22
0.93
Interest Coverage No Debt
Interest Coverage ranked lower than
72.40% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
CNCE: No Debt
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 80.22, Med: 5056.84, Max: 10000
Current: 10000
80.22
10000
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.47
DISTRESS
GREY
SAFE
Beneish M-Score -19.60
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -1385.45%
WACC 5.15%

Profitability & Growth : 1/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -7000.10
Operating Margin ranked higher than
97.73% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
CNCE: -7000.1
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -29406.32, Med: -101.56, Max: 64.39
Current: -7000.1
-29406.32
64.39
Net Margin % -7118.04
Net Margin ranked higher than
97.10% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
CNCE: -7118.04
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -29149.43, Med: -108.63, Max: 66.47
Current: -7118.04
-29149.43
66.47
ROE % -40.15
ROE ranked higher than
98.08% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CNCE: -40.15
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -46.91, Med: -2.35, Max: 67.51
Current: -40.15
-46.91
67.51
ROA % -35.53
ROA ranked higher than
98.80% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CNCE: -35.53
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -51.03, Med: -25.32, Max: 61.28
Current: -35.53
-51.03
61.28
ROC (Joel Greenblatt) % -724.38
ROC (Joel Greenblatt) ranked higher than
98.36% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CNCE: -724.38
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -2231.9, Med: -362.86, Max: 4406.69
Current: -724.38
-2231.9
4406.69
3-Year Total Revenue Growth Rate -46.00
3-Year Revenue Growth Rate ranked higher than
96.16% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
CNCE: -46.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -82.4, Med: -32.2, Max: 124.7
Current: -46.8
-82.4
124.7

» CNCE's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CNCE

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:PTGX NAS:XFOR NAS:MRSN NAS:TOCA NAS:XENE XTAE:KMDA NAS:ZYNE XTER:MDG1 NAS:ATHX NAS:CALA NAS:UROV XBRU:CYAD NAS:NVAX NAS:CERC NAS:MRKR SHSE:603139 NAS:PETX AMEX:XXII TPE:1760 AMEX:OCX
Traded in other countries 73C.Germany
Address 65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the current approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

Ratios

Current vs industry vs history
PB Ratio 1.68
PB Ratio ranked higher than
76.92% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CNCE: 1.68
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.48, Med: 2.48, Max: 5.31
Current: 1.68
1.48
5.31
PS Ratio 245.91
PS Ratio ranked higher than
84.71% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
CNCE: 245.91
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2.28, Med: 21.54, Max: 3777.5
Current: 245.91
2.28
3777.5
EV-to-EBIT -1.37
EV-to-EBIT ranked higher than
86.59% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CNCE: -1.37
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -6.7, Med: -2.25, Max: 24.3
Current: -1.37
-6.7
24.3
EV-to-EBITDA -1.40
EV-to-EBITDA ranked higher than
87.54% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CNCE: -1.4
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -7.1, Med: -2.3, Max: 23.4
Current: -1.4
-7.1
23.4
EV-to-Revenue 95.46
EV-to-Revenue ranked higher than
94.55% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
CNCE: 95.46
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -0.7, Med: 11.2, Max: 3255.3
Current: 95.46
-0.7
3255.3
Current Ratio 20.44
Current Ratio ranked higher than
96.83% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CNCE: 20.44
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 2.14, Med: 17.48, Max: 33.89
Current: 20.44
2.14
33.89
Quick Ratio 20.44
Quick Ratio ranked higher than
96.83% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CNCE: 20.44
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 2.14, Med: 17.48, Max: 33.89
Current: 20.44
2.14
33.89
Days Sales Outstanding 3.89
Days Sales Outstanding ranked higher than
99.85% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
CNCE: 3.89
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 0.37, Med: 1.48, Max: 56.64
Current: 3.89
0.37
56.64

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.80
3-Year Share Buyback Rate ranked higher than
65.58% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CNCE: -1.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -25.5, Med: -9, Max: -1.8
Current: -1.8
-25.5
-1.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.70
Price-to-Tangible-Book ranked higher than
82.44% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
CNCE: 1.7
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.69, Med: 2.61, Max: 5.13
Current: 1.7
1.69
5.13
Price-to-Projected-FCF 1.86
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
100.00% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
CNCE: 1.86
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.85, Med: 1.95, Max: 2.07
Current: 1.86
1.85
2.07
Price-to-Median-PS-Value 11.39
Price-to-Median-PS-Value ranked higher than
88.94% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
CNCE: 11.39
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.09, Med: 1.09, Max: 174.38
Current: 11.39
0.09
174.38
Earnings Yield (Joel Greenblatt) % -74.06
Earnings Yield (Greenblatt) ranked higher than
96.76% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CNCE: -74.06
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -116, Med: -18.6, Max: 2313.9
Current: -74.06
-116
2313.9

More Statistics

Revenue (TTM) (Mil) $ 1.03
EPS (TTM) $ -3.13
Beta 0.46
Volatility % 38.28
52-Week Range $ 9.21 - 20.79
Shares Outstanding (Mil) 23.8

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N